Skip to main content

Advertisement

Table 1 Incidence rate and excess risk attributable to statins for myopathy, hepatic disorder and diabetes

From: Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis

Author, year Incidence/10.000 person-years or % (95% CI) Excess risk/10.000 person-years or % Exposure definition Outcome definition
Myopathy
Gaist et al.[50] 2.30 2.10 One prescription and additional 30 days supply Medical codes for myopathic events and validation by independent blind review of medical records
(1.20 to 4.40)
Hippisley-Cox et al.[55] 0.26% 0.22% First prescription after January 2002 Medical codes for moderate or serious myopathic events (myopathy or rhabdomyolysis or a CK ≥4X ULN)
(0.24% to 0.28%)  
McClure et al.[77] 9.06 5.77 One prescription during the study period Medical codes for myopathy and CK ≥10X ULN
(n.r.)
Smeeth et al.[94] 0.11% 0.08% First prescription after January 1995 Medical codes for myositis or myolysis
(n.r.)
Hepatic disorder
Hippisley-Cox et al.[55] 1.20% 0.50% First prescription after January 2002 ALT ≥120 IU/l among patients without chronic liver disease
(1.13% to 1.22%)  
Smeeth et al.[94] 1.60% 0.30% First prescription after January 1995 Medical codes for acute liver disease
First year only 0.44% 0.16%
(n.r.)
Diabetes
Culver et al.[41] 6.25% 2.25% One prescription at the first screening interview and three-year follow-up Self-report of a new physician diagnosis of treated diabetes
(5.71% to 6.84%)
Jick et al.[59] n.a. n.a. Two prescriptions one year before index date Medical code for first diagnosis of diabetes plus more than two prescriptions for a hypoglycaemic agent or three records of diet management
  1. ALT, alanine transaminase; CK, creatine kinase; n.a., not applicable in a nested case control study; n.r., confidence intervals not reported; ULN, upper limit of normal.